Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies

International Journal of Pharmaceutics

Volumn 500, Issue 1-2, 2016, Pages 154-161

  Guada, Melissa ^a,b   Lasa Saracíbar, Beatriz ^a   Lana, Hugo ^a   Del Carmen Dios Viéitez, Maria ^a   Blanco Prieto, Maria J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Bioavailability; Caco 2 cells; Cyclosporine A; Gastrointestinal stability; Lipid nanoparticles; Oral route; Tissue distribution

Indexed keywords

CYCLOSPORIN A; GLYCEROL PALMITOSTEARATE; LIPID NANOPARTICLE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; CYCLOSPORIN; DIACYLGLYCEROL; IMMUNOSUPPRESSIVE AGENT; POLYSORBATE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; STOMACH PH; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CACO-2 CELL LINE; CHEMISTRY; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CYCLOSPORINE; DIGLYCERIDES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MICE, INBRED BALB C; NANOPARTICLES; PHOSPHATIDYLCHOLINES; POLOXAMER; POLYSORBATES; TAUROCHOLIC ACID;

EID: 84958826602     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.01.037     Document Type: Article

References (32)

1. max sparing the kidney from damage J. Biomed. Nanotechnol. 7 2011 300 307
2. A. Beloqui, M.Á. Solinís, A.R. Gascón, A. del Pozo-Rodríguez, A. des Rieux, and V. Préat Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier J. Controlled Release 166 2013 115 123
3. A. Beloqui, M.Á. Solinís, A. des Rieux, V. Préat, and A. Rodríguez-Gascón Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs Int. J. Pharm. 468 2014 105 111
4. J. Boland, K. Atkinson, K. Britton, P. Darveniza, S. Johnson, and J. Biggs Tissue distribution and toxicity of cyclosporin A in the mouse Pathology 16 1984 117 123
5. Y.Y. Chiu, K. Higaki, B.L. Neudeck, J.L. Barnett, L.S. Welage, and G.L. Amidon Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells Pharm. Res. 20 2003 749 756
6. M.G. Choc Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune® Int. J. Dermatol. 36 1997 1 6
7. Y.A. Choi, Y.H. Yoon, K. Choi, M. Kwon, S.H. Goo, J. Cha, M. Choi, H.S. Lee, and I. Song Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and tween80 in rats Biol. Pharm. Bull. 38 2015 208 217
8. W. Dai, Y. Guo, H. Zhang, X. Wang, and Q. Zhang Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A Int. J. Pharm. 478 2015 718 725
9. S. Das, and A. Chaudhury Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery AAPS PharmSciTech 12 2011 62 76
10. S. Deferme, P. Annaert, and P. Augustijns In vitro screening models to assess intestinal drug absorption and metabolism C. Ehrhardt, K. Kim, Drug Absorption Studies: in Situ, in Vitro and in Silico Models vol. 7 2007 Springer Science & Business Media NY, USA 182 215
11. V.C. Dias, and R.W. Yatscoff An in vitro method for predicting in vivo oral bioavailability of novel immunosuppressive drugs Clin. Biochem. 29 1996 43 49
12. A.G. Erlejman, C.G. Fraga, and P.I. Oteiza Procyanidins protect Caco-2 cells from bile acid-and oxidant-induced damage Free Radic. Biol. Med. 41 2006 1247 1256
13. A. Estella-Hermoso de Mendoza, M.A. Campanero, H. Lana, J.A. Villa-Pulgarin, J. de la Iglesia-Vicente, F. Mollinedo, and M.J. Blanco-Prieto Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles Nanomedicine 7 2012 679 690
14. M. Guada, E. Imbuluzqueta, A. Estella-Hermoso de Mendoza, H. Lana, M.C. Dios-Vieitez, and M.J. Blanco-Prieto Ultra high performance liquid chromatography-tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 927 2013 164 172
15. M. Guada, V. Sebastián, S. Irusta, E. Feijoó, M.C. Dios-Viéitez, and M.J. Blanco-Prieto Lipid nanoparticles for Cyclosporine A administration: development, characterization and in vitro evaluation of their immunosuppression activity Int. J. Nanomed. 10 2015 6541 6553
16. F. Ingels, S. Deferme, E. Destexhe, M. Oth, G. Van den Mooter, and P. Augustijns Simulated intestinal fluid as transport medium in the Caco-2 cell culture model Int. J. Pharm. 232 2002 183 192
17. P. Kaur, T. Garg, G. Rath, R.R. Murthy, and A.K. Goyal Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design Drug Deliv. 2014 1 14
18. B. Lasa-Saracíbar, M. Guada, V. Sebastián, and M.J. Blanco-Prieto In vitro intestinal co-culture cell model to evaluate intestinal absorption of edelfosine lipid nanoparticles Curr. Top. Med. Chem. 14 2014 1124 1132
19. Y. Lei, Y. Lu, J. Qi, S. Nie, F. Hu, W. Pan, and W. Wu Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility Int. J. Nanomed. 6 2011 795 805
20. R.H. Müller, S. Runge, V. Ravelli, W. Mehnert, A.F. Thünemann, and E.B. Souto Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals Int. J. Pharm. 317 2006 82 89
21. C. Olbrich, and R. Müller Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures Int. J. Pharm. 180 1999 31 39
22. E. Roger, F. Lagarce, E. Garcion, and J. Benoit Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis J. Controlled Release 140 2009 174 181
23. C. Schimpel, B. Teubl, M. Absenger, C. Meindl, E. Fröhlich, G. Leitinger, A. Zimmer, and E. Roblegg Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles Mol. Pharm. 11 2014 808 818
24. P. Shah, V. Jogani, T. Bagchi, and A. Misra Role of caco-2Cell monolayers in prediction of intestinal drug absorption Biotechnol. Prog. 22 2006 186 198
25. M.K. Shah, P. Madan, and S. Lin Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model Pharm. Dev. Technol. 2014 1 9
26. L. Shi, Y. Cao, X. Zhu, J. Cui, and Q. Cao Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model Int. J. Pharm. 478 2015 60 69
27. A. Spernath, A. Aserin, L. Ziserman, D. Danino, and N. Garti Phosphatidylcholine embedded microemulsions: physical properties and improved Caco-2 cell permeability J. Controlled Release 119 2007 279 290
28. S.A. Survase, L.D. Kagliwal, U.S. Annapure, and R.S. Singhal Cyclosporin A - a review on fermentative production: downstream processing and pharmacological applications Biotechnol. Adv. 29 2011 418 435
29. Y. Tan, J. Qi, Y. Lu, F. Hu, Z. Yin, and W. Wu Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells Toxicol. In Vitro 27 2013 714 720
30. K. Wang, J. Qi, T. Weng, Z. Tian, Y. Lu, K. Hu, Z. Yin, and W. Wu Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems Int. J Nanomedicine 9 2014 4991
31. Y. Zhang, X. Li, Y. Zhou, Y. Fan, X. Wang, Y. Huang, and Y. Liu Cyclosporin A-loaded poly (ethylene glycol)-b-poly (d, l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier Mol. Pharm. 7 2010 1169 1182
32. A. des Rieux, V. Fievez, I. Théate, J. Mast, V. Préat, and Y. Schneider An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells Eur. J. Pharm. Sci. 30 2007 380 391